Recent Articles By The Author
Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.
Few parts of the market have more volatility than the small caps in this sector.
A look at the financials as earnings season kicks into high gear.
Here are updates on small biotech/biopharma names I have profiled before.
The way I do that is by using buy-write option strategies.
Construction spending hasn't sent ambivalent signals in 2019.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.